NCT06938789 How Bleeding Affects Delirium in Older Patients With Hip Fractures: The IMPROVE-HIP Study
| NCT ID | NCT06938789 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Aarhus |
| Condition | Bleeding |
| Study Type | INTERVENTIONAL |
| Enrollment | 198 participants |
| Start Date | 2025-04-24 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 198 participants in total. It began in 2025-04-24 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to investigate whether early detection of bleeding and prompt blood transfusions can help prevent delirium in patients aged 75 and older who are admitted to the hospital with hip fractures. The main question the trial aims to answer is: Do patients aged 75 and older with hip fractures benefit from earlier treatment of anemia (low blood count) to reduce the risk of delirium? Researchers will compare early diagnosis and treatment of bleeding with standard care to determine if it helps lower the risk of developing delirium. Participants will: Undergo blood tests, have their vital signs monitored, and be screened for delirium three times a day for the first 48 hours after surgery. Receive blood transfusions promptly if their hemoglobin levels fall below a specified threshold. Attend a follow-up visit at 30 days to assess cognitive function and overall quality of life. Attend another follow-up at 90 days to evaluate hospital readmissions and survival.
Eligibility Criteria
Inclusion Criteria: * Hip fracture Exclusion Criteria: * Pathological hip fracture * Periprosthtic fracture * Unable to speak or understand Danish * Does not wish to recieve blood transfusion * If the investigator finds the patient unable to cooperate to the study (e.g. in case of severe dementia and externalizing behaviour)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06938789 clinical trial?
This trial is open to participants of all sexes, aged 75 Years or older, studying Bleeding. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06938789 currently recruiting?
Yes, NCT06938789 is actively recruiting participants. Contact the research team at jobech@clin.au.dk for enrollment information.
Where is the NCT06938789 trial being conducted?
This trial is being conducted at Aarhus, Denmark, Herning, Denmark.
Who is sponsoring the NCT06938789 clinical trial?
NCT06938789 is sponsored by University of Aarhus. The trial plans to enroll 198 participants.